Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
View Patent ↗The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone.
1. A method, comprising:
a) providing;
i) a cell line comprising a stably transfected recombinant plasmid vector encoding a chimeric TSH receptor and a reporter gene, wherein said chimeric TSH receptor is encoded by a nucleic acid sequence comprising SEQ ID NO: 3;
ii) a cell culture medium compatible with said cell line; and
iii) a serum sample derived from a patient suspected of having Graves' disease;
b) contacting the serum sample with the cell line and the medium under conditions such that a reporter gene emits a detectable signal upon induction by a TSH receptor-specific stimulating auto-antibody.
2. The method of claim 1 , wherein an intensity of said detectable signal correlates with clinical activity.
3. The method of claim 1 , wherein an intensity of said detectable signal correlates with the clinical severity of Graves' disease.
4. The method of claim 3 wherein said clinical severity is assessed on the basis of diplopia, proptosis, visual acuity, ocular motility, optic neuropathy, or extra-ocular muscle thickness.
5. The method of claim 3 , wherein said clinical severity is measured on the basis of the NOSPECS score.
6. The method of claim 1 , wherein an intensity of said detectable signal correlates with Graves' orbitopathy.
7. The method of claim 1 , wherein the thyrotropin stimulating hormone receptor autoantibody concentration correlates with clinical activity.
8. The method of claim 1 , wherein the thyrotropin stimulating hormone receptor autoantibody concentration correlates with the clinical severity of Graves' disease.
9. The method of claim 8 , wherein the clinical severity is assessed on the basis of diplopia, proptosis, visual acuity, ocular motility, optic neuropathy, or extra-ocular muscle thickness.
10. The method of claim 8 , wherein said clinical severity is measured on the basis of the NOSPECS score.
11. The method of claim 1 , wherein the thyrotropin stimulating hormone receptor autoantibody concentration correlates with Graves' orbitopathy.
12. The method of claim 1 , wherein said culture medium contains a glucocorticoid.
13. The method of claim 1 , wherein said reporter gene is luciferase.
14. A method, comprising:
a) providing:
i) a cell line comprising a stably transfected recombinant plasmid vector encoding a chimeric TSH receptor and a reporter gene, wherein said chimeric TSH receptor is encoded by a nucleic acid sequence comprising SEQ ID NO: 3;
ii) a cell culture medium compatible with said cell line; and
iii) an undiluted serum sample and a diluted serum sample from a patient suspected of having Graves' disease;
b) contacting the undiluted serum sample and diluted serum sample with the cell line and the medium under conditions such that a reporter gene emits a detectable signal upon induction by a TSH receptor-specific stimulating auto-antibody.
15. The method of claim 14 , wherein said method further comprises step c) comparing an intensity of said detectable signal from said undiluted sample with said diluted sample.
16. The method of claim 15 , wherein said activity from undiluted and diluted serum demonstrates a comparative reactivity profile indicative of clinical activity.
17. The method of claim 15 , wherein said activity from undiluted and diluted serum demonstrates a comparative reactivity profile indicative of severity of Graves' disease.
18. The method of claim 15 , wherein said activity from undiluted and diluted serum demonstrates a comparative reactivity profile indicative for Graves' orbitopathy.
19. The method of claim 14 , wherein said culture medium contains a glucocorticoid.
20. The method of claim 14 , wherein said reporter gene is luciferase.
21. A method, comprising:
a) providing;
i) a cell line comprising a stably transfected recombinant plasmid vector encoding a chimeric TSH receptor and a reporter gene, wherein said chimeric TSH receptor is encoded by a nucleic acid sequence comprising SEQ ID NO: 3;
ii) a cell culture medium compatible with said cell line;
iii) a first undiluted serum sample obtained from a patient having Graves' disease prior to being treated with drug therapy; and
iv) a second undiluted serum sample obtained from a patient having Graves' disease after being treated with drug therapy;
b) diluting a portion of said first serum to create a diluted first serum sample; and
c) contacting said undiluted first serum sample and said diluted first serum sample with the cell line and the medium under conditions such that a reporter gene emits a detectable signal upon induction by a TSH receptor-specific stimulating auto-antibody.
22. The method of claim 21 , wherein said method further comprises step d) diluting a portion of said second serum sample to create a diluted second serum sample; and e) contacting the undiluted second serum sample and diluted second serum sample with the cell line and the medium under conditions such that a reporter gene emits a detectable signal upon induction by a TSH receptor-specific stimulating auto-antibody.
23. The method of claim 22 , further comprising step f) comparing the activity of the expressed reporter gene from the first and second serum samples.
24. The method of claim 23 , wherein the comparative reactivity profiles of the first and second serum samples serve as an indication of patient response to drug treatment.
25. The method of claim 21 , wherein said culture medium contains a glucocorticoid.
26. The method of claim 21 , wherein said reporter gene is luciferase.
27. The method of claim 21 , wherein the drug received by said patients is selected from the group consisting of anti-thyroid drugs, steroids, T4, and immunosuppressive drugs.
28. The method of claim 21 , wherein the thyrotropin stimulating hormone receptor auto-antibody concentration is used to monitor drug treatment.